Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. Baranova, V. Perlej, A. Speranskaja, S. Kabanova (Saint-Petersburg, Russian Federation). Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS). Eur Respir J 2008; 32: Suppl. 52, 3433

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary hypertension (PH) and features of pulmonary circulation in patient with lung sarcoidosis (LS) Source: Eur Respir J 2006; 28: Suppl. 50, 354s Year: 2006 Bosentan treatment in pulmonary arterial hypertension (PAH) associated with interstitial lung diseases (ILDs) Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006 6MWD in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 464s Year: 2003 Characteristics of idiopathic pulmonary arterial hypertension (IPAH) and PAH associated with connective tissue disease (APAH-CTD) patients in PROSPECT Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Pulmonary artery dissection (PAD) in a patient with diffuse interstitial lung disease and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Exhaled breath olfactory signature of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Contrasting physiological responses to the six minute walk test in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Pulmonary hypertension (PH) in chronic hemodialysis (CHD) patients is associated with inflammatory markers and volume overload Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Comparison of activities of daily living in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2016 – Best abstracts in exercise capacity and testing in chronic lung diseases Year: 2016 Incidence and outcomes of haemoptysis in patients with operable and non-operable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Pulmonary arterial hypertension (PAH) in primary Sjögren‘s syndrome: report of 9 cases Source: Eur Respir J 2007; 30: Suppl. 51, 344s Year: 2007 Comparison of subcutaneous (sc) treprostinil use for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in 2 Belgian centers Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010 Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension Year: 2019 Sildenafil decreases the contractile response to serotonin (5HT) in pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Bosentan for sarcoidosis associated pulmonary arterial hypertension (BoSAPH) was effective in advanced parenchymal lung disease Source: Annual Congress 2012 - Sarcoidosis Year: 2012 The right ventricle (RV) in systemic sclerosis-associated pulmonary arterial hypertension (SSCPH) vs idiopathic pulmonary arterial hypertension (IPH): higher inflammatory status, no increase in interstitial fibrosis Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Pulmonary arterial hypertension (PAH) among end state renal disease (ESRD) patients under chronic hemodyalisis (HD) Source: Eur Respir J 2007; 30: Suppl. 51, 345s Year: 2007 Pregnancy and pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II Year: 2013 Comparison of pulmonary hypertension (PH) associated to chronic lung disease to other PH groups Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016